Summary

Eligibility
for people ages up to 30 years (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Elliot Stieglitz (ucsf)
Headshot of Elliot Stieglitz
Elliot Stieglitz

Description

Summary

This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults.

This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of physicians, scientists and pharmacists. This may result in a recommendation for a specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the participant's primary oncologist.

Official Title

Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome

Details

Keywords

Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy, Leukemia, Preleukemia, Myelodysplastic Syndromes, Recurrence, Leukemia Profiling, Relapsed/Refractory Leukemia, New Diagnosis

Eligibility

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • Seattle Children's Hospital
    Seattle Washington 98105 United States

Lead Scientist at University of California Health

  • Elliot Stieglitz (ucsf)
    Juvenile myelomonocytic leukemia (JMML) is a blood cancer that affects young children and is difficult to diagnose. Currently available therapies cure only half of patients, with some children experiencing an aggressive disease course while some children get better with very little treatment. We have now shown that the presence of secondary mutations at diagnosis predicts a poor outcome.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dana-Farber Cancer Institute
ID
NCT02670525
Study Type
Interventional
Participants
About 338 people participating
Last Updated